Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study
Qing Zhou, Chong-Rui Xu, Ying Cheng, Yun-Peng Liu, Gong-Yan Chen, Jiu-Wei Cui, Nong Yang, Yong Song, Xiao-Ling Li, Shun Lu, Jian-Ying Zhou, Zhi-Yong Ma, Shi-Ying Yu, Cheng Huang, Yong-Qian Shu, Zhen Wang, Jin-Ji Yang, Hai-Yan Tu, Wen-Zhao Zhong, Yi-Long Wu, Qing Zhou, Chong-Rui Xu, Ying Cheng, Yun-Peng Liu, Gong-Yan Chen, Jiu-Wei Cui, Nong Yang, Yong Song, Xiao-Ling Li, Shun Lu, Jian-Ying Zhou, Zhi-Yong Ma, Shi-Ying Yu, Cheng Huang, Yong-Qian Shu, Zhen Wang, Jin-Ji Yang, Hai-Yan Tu, Wen-Zhao Zhong, Yi-Long Wu
Abstract
Dual inhibition of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) pathways may delay therapeutic resistance in advanced non-small cell lung cancer (NSCLC). This phase 3 study investigated the efficacy and safety of an erlotinib plus bevacizumab regimen in untreated patients with advanced NSCLC. In total, 311 patients received bevacizumab plus erlotinib (n = 157) or erlotinib only (n = 154). Progression-free survival (PFS) was 17.9 months (95% confidence interval [CI], 15.2-19.9) for bevacizumab plus erlotinib and 11.2 months (95% CI, 9.7-13.8) for erlotinib only (hazard ratio [HR] = 0.55; 95% CI, 0.41-0.73; p < 0.001). A brain metastases subgroup treated with bevacizumab plus erlotinib also showed improved PFS (HR = 0.48; 95% CI, 0.27-0.84; p = 0.008). Grade ≥3 treatment-related adverse events occurred in 86 (54.8%) and 40 (26.1%) patients, respectively. Bevacizumab plus erlotinib significantly improved PFS in patients with untreated metastatic EGFR-mutated NSCLC, including those with brain metastases at baseline.
Keywords: EGFR mutation; bevacizumab; epidermal growth factor receptor inhibitor; erlotinib; non-small cell lung cancer; vascular endothelial growth factor inhibitor.
Conflict of interest statement
Declaration of interests Y.-L.W. reports advisory services for AstraZeneca, Boehringer Ingelheim, Novartis, Takeda; personal fees from AstraZeneca, Beigene, Boehringer Ingelheim, BMS, Eli Lilly, MSD, Pfizer, Roche, Sanofi; grants from AstraZeneca, Boehringer Ingelheim, BMS, Hengrui, and Roche, outside the submitted work. Q.Z. reports honoraria from AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, MSD, Pfizer, Roche, and Sanofi, outside the submitted work. W.-Z.Z. reports honoraria from AstraZeneca, Eli Lilly, Pfizer, Roche, and Sanofi, outside the submitted work. All other authors declare no competing interests.
Copyright © 2021 Elsevier Inc. All rights reserved.
Source: PubMed